This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zimmer Biomet (ZBH) Q1 Earnings Beat Estimates, View Raised
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions records strong year-over-year sales growth at CER.
Hologic's (HOLX) Q2 Earnings Beat Estimates, 2023 View Up
by Zacks Equity Research
The year-over-year growth in Breast Health and GYN Surgical Businesses contributed to Hologic's (HOLX) Q2 revenues.
IDEXX (IDXX) Q1 Earnings Beat Estimates, Margins Increase
by Zacks Equity Research
Continued solid demand for veterinary services and record global premium instrument placements drive IDEXX's (IDXX) Q1 revenues.
Ecolab (ECL) Q1 Earnings & Revenues Beat, Margins Up
by Zacks Equity Research
Ecolab's (ECL) robust performance across all segments drives its Q1 sales despite business challenges.
Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Despite Avantor's (AVTR) strength in bioproduction and strength in Applied Technologies and Advanced Materials end markets, it reports an overall soft Q1 performance.
Stryker (SYK) Q1 Earnings Beat Estimates, Volume Improves
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.
These 3 Large-Caps Roared in April
by Derek Lewis
These stocks' performances raise a valid question: can they keep climbing, or has the move already ended?
Merit Medical (MMSI) Tops Q1 Earnings Estimates, Ups FY23 View
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the first quarter.
Integer Holdings (ITGR) Q1 Earnings, Revenues Beat Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect robust Medical and Non-Medical sales, besides strength in all the product lines.
DexCom (DXCM) Q1 Earnings Beat Estimates, Volumes Remain Strong
by Zacks Equity Research
DexCom's (DXCM) first-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ResMed (RMD) reports a solid third-quarter top line, led by strong device sales growth through steady production and delivery of its cloud-connected flow generator devices to meet high market demand.
Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Baxter (BAX) Beats on Q1 Earnings, Ups '23 EPS View
by Zacks Equity Research
Baxter's (BAX) first-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.
Accuray (ARAY) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Accuray (ARAY) reports a solid fiscal third-quarter top line on the back of robust segmental performances.
Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.
West Pharmaceutical (WST) Q1 Earnings Beat, Order Book Strong
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.
Surmodics (SRDX) Q2 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal second-quarter top line on the back of robust Medical Device revenues.
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms Guidance
by Zacks Equity Research
Strength in the VITAS and Roto-Rooter branches contributes to Chemed's (CHE) first-quarter top line.
CONMED (CNMD) Beats on Q1 Earnings, Ups '23 EPS View
by Zacks Equity Research
CONMED's (CNMD) adjusted first-quarter sales and earnings recover from the disruption in the fourth quarter due to implementation of a new warehouse management system.
Healthcare: An Essential Sector (3 Stocks to Buy Ahead of Earnings)
by Andrew Rocco
Healthcare stocks are an excellent place to park your money in the current market environment. Due to it's necessity, the sector tends to due well in any economy.
Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ANIXA BIOSCIENCES INC (ANIX) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.
Zacks Investment Ideas feature highlights: Nasdaq 100 ETF, Dexcom, Merck, Intuitive Surgical and SPDR S&P Regional Bank ETF
by Zacks Equity Research
Nasdaq 100 ETF, Dexcom, Merck, Intuitive Surgical and SPDR S&P Regional Bank ETF have been highlighted in this Investment Ideas article.
Sell the News? 5 Reasons Tech May Pullback
by Andrew Rocco
Though the medium-term trend remains intact for tech, some subtle signs of weakness are appearing beneath the surface. Andrew Rocco breaks it down.
Zacks Investment Ideas feature highlights: Nvidia, First Solar, Intuitive Surgical, Dexcom and Asure Software
by Zacks Equity Research
Nvidia, First Solar, Intuitive Surgical, Dexcom and Asure Software are part of the Zacks Investment Ideas article.
Riding the Wave: These 3 Industry Groups are Making a Splash with Expected Money Inflows
by Andrew Rocco
Markets have been known to have periods of "nasty" industry group rotation. Get ahead of the curve with these 3 under-the-radar groups.